Results 161 to 170 of about 398,650 (328)
This review aims to provide a broad understanding for interdisciplinary researchers in engineering and clinical applications. It addresses the development and control of magnetic actuation systems (MASs) in clinical surgeries and their revolutionary effects in multiple clinical applications.
Yingxin Huo+3 more
wiley +1 more source
The Quantitative Application of Radioactivity Logs [PDF]
R.E. Bush, E.S. Mardock
openalex +1 more source
Herein, a patient‐mounted neuro optical coherence tomography system that integrates a 5 degrees‐of‐freedom skull‐mounted robot (Skullbot) with a 0.6 mm neuroendoscope for targeted, minimally invasive deep brain imaging, is developed. The system offers high‐resolution imaging with precise deployment, demonstrated through successful tumor imaging in a ...
Chao Xu+7 more
wiley +1 more source
XXXI. On the radioactivity of potassium and other alkali metals [PDF]
John Cunningham McLennan, W.T. Kennedy
openalex +1 more source
Insect‐Inspired Resilient Machines
This study presents a decentralized resilient control for legged robots, enabling self‐organized locomotion and rapid adaptation to extreme leg loss within seconds. It encodes the self‐embodied resilience strategies observed in stick insects and relies on neural dynamics with synaptic plasticity, minimal sensory feedback, and dynamic robot–environment ...
Thirawat Chuthong+3 more
wiley +1 more source
XXIII. The radioactivity of archœan rocks from the Mysore State, South India [PDF]
William F Smeeth, Harry Watson
openalex +1 more source
Genomics Review of Selective RET Inhibitors Sensitivity in Thyroid Cancer Clinical Trials
ABSTRACT RET gene is a driver of thyroid cancer (TC) tumorigenesis. The incidence of TC has increased worldwide in the last few decades, both in medullary and follicular‐derived subtypes. Several drugs, including multikinase and selective inhibitors, have been explored.
Sara Gil‐Bernabé+5 more
wiley +1 more source
ABSTRACT Rare diseases impact approximately 1 in 10 people worldwide, and yet, less than 5% of all rare diseases currently have an approved treatment option available. This is due to many challenges unique to rare diseases, including small, diverse patient populations, the cost of drug development that is not proportionate to the number of patients who
Caleb P. Bupp+7 more
wiley +1 more source
II. On the radioactivity of the rocks of the transandine tunnel [PDF]
Arnold L. Fletcher
openalex +1 more source